Genitourinary Cancer News

In this video, Tanya Dorff, MD, discusses findings from a phase 1 study assessing prostate stem cell antigen-targeted CAR T-cell therapy in patients with castration-resistant prostate cancer.

Patients with urothelial carcinoma who experienced an immune-related adverse event following checkpoint blockade had significantly improved clinical outcomes, according to a poster presented at ASCO Genitourinary Cancers Symposium.

Pathogenic variants in BRCA1 and BRCA2 appeared associated with increased risks for prostate cancer, pancreatic cancer, male breast cancer and possibly stomach cancer, according to research published in Journal of Clinical Oncology.

Only 7.5% of oncology trials conducted between 2008 and 2020 investigated surgical interventions, according to study results published in JAMA Network Open.

SAN FRANCISCO — The addition of niraparib to best supportive care failed to extend PFS among patients with advanced urothelial carcinoma who did not experience progression after first-line platinum-based chemotherapy, study results showed.

SAN FRANCISCO — Certain immune cell-related parameters appeared associated with efficacy of immune checkpoint inhibitors among patients with advanced or metastatic clear cell renal cell carcinoma, according to study results.

SAN FRANCISCO — Axitinib combined with nivolumab demonstrated encouraging efficacy among treatment-naive patients with metastatic renal cell carcinoma, according to study results presented at ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — Addressing disparities in genitourinary cancers requires more research on changing risk factors and immediate actions aimed at prevention, Karen E. Knudsen, PhD, MBA, said during ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — Neoadjuvant treatment with enfortumab vedotin demonstrated promising activity among cisplatin-ineligible patients with muscle-invasive bladder cancer, according to study results presented at ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — Lenvatinib plus pembrolizumab did not demonstrate a positive benefit-risk ratio compared with pembrolizumab and placebo as first-line therapy for certain patients with advanced urothelial carcinoma, study results showed.